<DOC>
	<DOC>NCT01265706</DOC>
	<brief_summary>This study is performed to observe the incidence of major cardiovascular events in Korean patients with AMI after giving pitavastatin 2mg and 4mg longer than 1 year.</brief_summary>
	<brief_title>Livalo Acute Myocardial Infarction Study (LAMIS)</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Patients with STEMI, NSTEMI Patients satisfying at least one of the followings 1. Patients with LDLC ≥ 130 mg/dL 2. Patients with LDLC ≥ 100 mg/dL who are regarded as required cholesterol lowering therapy by the investigator 3. Patients taking statin are required continuous cholesterol lowering therapy Patients satisfying at least two of the followings 1. The change of Ischemic ECG 2. CK, CKMB, TroponinI increased more than two times 3. The symptom of ACS 1. Patients with instent restenosis after PCI or coronary artery bypass 2. Patients with cardiogenic shock 3. Patients with severe heart failure (Left ventricular ejection fraction is less than 30%) 4. Patients who are taking cyclosporine 5. Patients who experienced hypersensitivity to pitavastatin 6. Patients under dialysis treatment 7. Patients who are participating other clinical trials 8. Patients who can not stop taking concomitant drugs 9. Pregnant or lactating women or suspected pregnancy 10. Patients who are regarded as ineligible for this study by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
</DOC>